Dr Reddy's Laboratories and Merck Serono, a unit of Germany's Merck KGaA, have entered into a partnership to co-develop a portfolio of biosimilar compounds in the oncology segment
As per the deal, the two companies will co-develop the molecules included in the agreement. Dr Reddy's will lead early product development and complete phase I, and then Merck Serono will take over manufacturing of the compounds and will lead phase III development
The agreement is based on full R&D cost sharing
It will also handle commercialisation in large parts of the world and will pay Dr. Reddy's royalties.
http://www.business-standard.com/india/news/german-pharma-cosdr-reddys-to-cooperatebiosimilars/166952/on
No comments:
Post a Comment